KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target - PubMed (original) (raw)

Practice Guideline

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target

KDOQI. Am J Kidney Dis. 2007 Sep.

No abstract available

PubMed Disclaimer

Similar articles

• Target hemoglobin level for EPO therapy in CKD.
  Parfrey PS. Parfrey PS. Am J Kidney Dis. 2006 Jan;47(1):171-3. doi: 10.1053/j.ajkd.2005.11.001. Am J Kidney Dis. 2006. PMID: 16377399 No abstract available.
• [Regarding the optimal hemoglobin target range in renal anemia].
  Maurin N. Maurin N. Med Klin (Munich). 2008 Sep 15;103(9):633-7. doi: 10.1007/s00063-008-1102-3. Epub 2008 Sep 24. Med Klin (Munich). 2008. PMID: 18813886 Review. German.
• Triumph and tragedy: anemia management in chronic kidney disease.
  Novak JE, Szczech LA. Novak JE, et al. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):580-8. doi: 10.1097/MNH.0b013e32830c488d. Curr Opin Nephrol Hypertens. 2008. PMID: 18941350 Review.
• Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
  Wiecek A, Covic A, Locatelli F, Macdougall IC; ORAMA study group. Wiecek A, et al. Ren Fail. 2008;30(3):267-76. doi: 10.1080/08860220701857241. Ren Fail. 2008. PMID: 18350446
• Do we know the correct hemoglobin target for anemic patients with chronic kidney disease?
  Foley RN. Foley RN. Clin J Am Soc Nephrol. 2006 Jul;1(4):678-84. doi: 10.2215/CJN.01731105. Epub 2006 Jun 8. Clin J Am Soc Nephrol. 2006. PMID: 17699272 Review.

Cited by

• A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
  Liu J, Li S, Yang F, Li T, Li R, Waheed Y, Meng C, Li S, Liu K, Tong Y, Xu H, Tian C, Zhou X. Liu J, et al. Korean J Intern Med. 2024 May;39(3):488-500. doi: 10.3904/kjim.2023.520. Epub 2024 Apr 23. Korean J Intern Med. 2024. PMID: 38649158 Free PMC article.
• Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction.
  Matsuoka T, Abe M, Kobayashi H. Matsuoka T, et al. Int J Mol Sci. 2024 Mar 27;25(7):3745. doi: 10.3390/ijms25073745. Int J Mol Sci. 2024. PMID: 38612557 Free PMC article. Review.
• Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors and Hypothyroidism: An Analysis of the Japanese Pharmacovigilance Database.
  Tanaka H, Tani A, Onoda T, Ishii T. Tanaka H, et al. In Vivo. 2024 Mar-Apr;38(2):917-922. doi: 10.21873/invivo.13519. In Vivo. 2024. PMID: 38418113 Free PMC article.
• Risk factors and current state of therapy for anemia after kidney transplantation.
  Tang Y, Guo J, Zhou J, Wan Z, Li J, Qiu T. Tang Y, et al. Front Med (Lausanne). 2024 Jan 8;10:1170100. doi: 10.3389/fmed.2023.1170100. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38264045 Free PMC article. Review.
• Correlation between ultrafiltration rate and hemoglobin level and erythropoietin response in hemodialysis patients.
  Cui L, Zhang L, Li J, Li Y, Hao X, Xu Y, Li C. Cui L, et al. Ren Fail. 2024 Dec;46(1):2296609. doi: 10.1080/0886022X.2023.2296609. Epub 2024 Jan 4. Ren Fail. 2024. PMID: 38178573 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information